Whether these agents will continue to be needed by patients experiencing substantial health benefits from CFTR modulators remains to be seen, but there certainly remains an unmet need in those for whom modulators are not appropriate; such drugs may also be useful outside CF for other forms of bronchiectasis and chronic obstructive pulmonary disease (COPD) for which treatments are currently lacking62. The gene discussed is CFTR; the disease is bronchiectasis.